🔎 Trials Near Me

Utama › Kanser Paru-paru Bukan Sel Kecil › Florida › West Palm Beach

Kajian klinikal Kanser Paru-paru Bukan Sel Kecil di West Palm Beach, FL

13 kajian untuk Kanser Paru-paru Bukan Sel Kecil sedang mencari peserta di lokasi dalam dan sekitar West Palm Beach (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Mengambil pesertaFasa 2
  • Florida Cancer Specialists - East /ID# 271993, West Palm Beach
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Okt 2026 · NCT06568939

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Mengambil pesertaFasa 3
  • Florida Cancer Specialists & Research Institute - East, West Palm Beach
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT06881784

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Mengambil pesertaFasa 3
  • Florida Cancer Specialists - East, West Palm Beach
  • Florida Cancer Specialists, Palm Beach Gardens · 9 mi jauh
  • Florida Cancer Specialists, Wellington · 12 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07222566

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Mengambil pesertaFasa 2
  • Florida Cancer Specialists & Research Institute, West Palm Beach
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06667076

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Mengambil pesertaFasa 3
  • Florida Cancer Specialists East, West Palm Beach
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06890598

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Mengambil pesertaFasa 3
  • Florida Cancer Specialists - East, West Palm Beach
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT06561386

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Mengambil pesertaFasa 3
  • Clinical Study Site, West Palm Beach
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT06767514

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Mengambil pesertaFasa 2/3
  • SCRI - Florida Cancer Specialists - West Palm Beach, West Palm Beach
  • Local Institution - 007-926-A, Wellington · 12 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT04613596

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Mengambil pesertaFasa 3
  • Research Site, West Palm Beach
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT07291037

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Mengambil pesertaFasa 1/2
  • USOR Florida Cancer Specialists East, West Palm Beach
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Ogo 2026 · NCT05579366

Kajian Kanser Paru-paru Bukan Sel Kecil di bandar lain

Kajian lain di West Palm Beach

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.